BridgeBio Oncology Therapeutics

BBOT (NasdaqGM)

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company developing orally available small-molecule drugs. Its pipeline includes BBO-8520, a direct KRASG12C inhibitor in Phase I for KRASG12C mutant NSCLC; BBO-11818, a pan-KRAS inhibitor in Phase I for KRAS G12D/G12V models; and BBO-10203 in Phase I for HER2+ and HR+/HER2- breast cancer, plus KRAS mutant CRC and NSCLC, along with precision oncology assets. Founded in 2016, based in South San Francisco, California.